Issues
-
Cover Image
Cover Image
Twist1 is a key inducer of epithelial-mesenchymal transition during tumor metastasis and is upregulated in aggressive human cancers. A new role for Twist1 in tumor progression was uncovered, showing that Twist1 is capable of stimulating angiogenesis via CCL2 production and subsequent recruitment of macrophages from the tumor stroma. Using a Matrigel plug assay, the images show that mouse mammary tumor cells endogenously expressing high levels of Twist1 stimulated a strong angiogenic response, seen as red blood vessels in the isolated plugs. When Twist1 expression was suppressed in these cells, the angiogenic response was diminished. For details, see the article by Low-Marchelli and colleagues on page 662. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Review
Perspective
Priority Reports
Clinical Studies
Integrated Systems and Technologies
Systems Analysis of BCL2 Protein Family Interactions Establishes a Model to Predict Responses to Chemotherapy
Microenvironment and Immunology
CD40-Mediated Activation of Chronic Lymphocytic Leukemia Cells Promotes Their CD44-Dependent Adhesion to Hyaluronan and Restricts CCL21-Induced Motility
CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma
Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance
Molecular and Cellular Pathobiology
SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer
Prevention and Epidemiology
Common Single-Nucleotide Polymorphisms in the Estrogen Receptor β Promoter Are Associated with Colorectal Cancer Survival in Postmenopausal Women
Therapeutics, Targets, and Chemical Biology
Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth
Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Specific Elimination of CD133+ Tumor Cells with Targeted Oncolytic Measles Virus
Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer
Tumor and Stem Cell Biology
Definition of Molecular Determinants of Prostate Cancer Cell Bone Extravasation
ΔNp63α-Mediated Activation of Bone Morphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells
Letters to the Editor
Retraction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.